Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.33 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5210225 | 0.89 | KDR (0.54) | KDRALKFGFR1MAPK8MAPK10 | |
| SCHEMBL5205632 | 0.87 | KDR (0.66) | KDRALKFGFR1MAPK8MAPK10 | |
| SCHEMBL5210372 | 0.82 | KDR (0.46) | KDRALKMAPK8MAPK10MAPK14 | |
| SCHEMBL5211172 | 0.81 | KDR (0.46) | KDRALKFGFR1MAPK8MAPK10 | |
| SCHEMBL5205340 | 0.80 | KDR (0.34) | KDR | |
| SCHEMBL5212977 | 0.79 | KDR (0.46) | KDRALKFGFR1MAPK8MAPK10 | |
| SCHEMBL5208847 | 0.70 | KDR (0.82) | KDRALKFGFR1MAPK8MAPK10 | |
| SCHEMBL5210216 | 0.70 | KDR (0.49) | KDRALKFGFR1MAPK8MAPK10 | |
| SCHEMBL5208858 | 0.70 | KDR (0.82) | KDRALKFGFR1MAPK8MAPK10 | |
| SCHEMBL5211081 | 0.70 | KDR (0.54) | KDRALKFGFR1MAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585743-B1 | 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES | PFIZER (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060160858-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2006-07-20 | — | — | US | disclosed |
| US-7053107-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1585743-A1 | 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES | PFIZER INC. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004056806-A1 | 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES | PFIZER INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | KDR 88/4885ALK 862/4885FGFR1 315/4885 |
| US-20060160858-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | KDR 88/4885ALK 862/4885FGFR1 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.